We are Creating innovative, impactful medicines. Play Pause Our Pipeline Driven by science, focused on people. We are focused on discovering and developing medicines that improve the lives of people by addressing conditions with high unmet medical need. Our growing pipeline of programs is deeply rooted in science, powered by our technology, and driven by

Work together, win together with an ownership stake in AbCellera. Personal & Professional Development . Ignite your curiosity, learn, and be inspired through workshops, conferences and programs. World Class Facilities . We have world class labs, office spaces, and gyms.

Nov 21, 2024 · AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems.

Our Focus First-in-class and best-in-class antibody medicines. Our Pipeline We are advancing programs to address unmet medical need in autoimmunity, endocrine and metabolic conditions, and beyond. We are leveraging our engine to generate a pipeline of programs with first-in-class and best-in-class potential. Our first two preclinical programs, ABCL575 and ABCL635, are …

Our Technologies Unlocking antibody drug targets, classes, and modalities. Our Platforms Expanding the reach of antibody therapeutics. We have developed technology platforms to unlock high-value drug classes, targets, and modalities, including transmembrane proteins and T-cell engagers. GPCRs & Ion Channels We are using our platform to develop first-in-class antibody …

At AbCellera, team is everything. When great people share a vision and work together, they can truly have a positive impact on the world. That’s why we hire for character and intelligence, not just for CVs or experience.

Strategic Partnerships Making medicines together. We strategically partner with groups that have novel science and innovative technology to develop antibody-based medicines. Our Impact Making a difference for patients. Since 2015, we have worked with more than 40 partners on 100+ antibody drug programs, with 14 candidates reaching the clinic to date. 100+ Antibody …

Presentations & Posters All Posts T-Cell Engagers GPCRs & Ion Channels T-Cell Engagers Profiling bispecific T-cell engagers: Strategies for enhancing potency while minimizing cytokine release Read more T-Cell Engagers Diverse CD28-binding antibodies for costimulatory T-cell engager development Read more T-Cell Engagers Development of PSMA x CD3 T-cell …

Find AbCellera (NASDAQ: ABCL) financial information and SEC filings.

The neutralizing antibody, LY-CoV555, protects against SARS–CoV–2 infection in nonhuman primates